Vumerity (diroximel fumarate) is an oral medication for relapsing forms of multiple sclerosis that works by converting into an active compound in your body, which then reduces inflammation and protects nerve cells from damage. It’s a prodrug, meaning the capsule you swallow isn’t the active medicine itself. Instead, enzymes in your gut rapidly break it down into the compound that does the real work.
From Capsule to Active Compound
After you swallow a Vumerity capsule, enzymes called esterases cleave it into two main pieces. The first is monomethyl fumarate (MMF), the only pharmacologically active metabolite. This is the molecule responsible for all of Vumerity’s therapeutic effects. The second is an inactive byproduct called 2-hydroxyethyl succinimide (HES), which your kidneys clear out through urine (about 58 to 63% of the dose leaves the body this way). MMF itself is mostly eliminated as carbon dioxide through exhaled breath, with less than 0.3% appearing in urine.
An older MS drug, Tecfidera (dimethyl fumarate), converts into the same active molecule. Vumerity was designed with a different chemical structure specifically to produce fewer gut-related side effects while delivering the same therapeutic benefit.
How It Reduces Inflammation
Once MMF enters your bloodstream, it targets the immune system through several overlapping pathways. The most well-studied involves a protein called Nrf2, which normally sits inactive inside cells. MMF triggers Nrf2 to move into the cell nucleus, where it switches on a set of genes that produce antioxidant and detoxifying enzymes. These enzymes neutralize the reactive oxygen species that fuel inflammatory damage in MS. In animal studies, this process significantly suppressed inflammatory signaling molecules like IL-1β and CCL2, and the effect disappeared entirely in animals engineered to lack the Nrf2 gene, confirming its central role.
Beyond Nrf2, MMF also activates a receptor on immune cells sometimes called the niacin receptor. When this receptor is triggered, it calms overactive immune cells called microglia in the brain and spinal cord, reducing neuroinflammation. It also blocks a key inflammatory signaling pathway (NF-kB) that controls the production of immune-stimulating proteins called cytokines. These multiple, overlapping mechanisms help explain why the drug is effective: it doesn’t rely on a single pathway to suppress the immune attack on nerve tissue.
How It Protects Nerve Cells
MS damages the protective myelin coating around nerve fibers, but it also harms the nerve cells themselves through oxidative stress. MMF crosses the blood-brain barrier, meaning it reaches the central nervous system directly. Once there, the same Nrf2-driven antioxidant response that reduces inflammation also shields neurons and the supporting glial cells from damage.
The neuroprotective effect has been demonstrated clearly in laboratory studies. In one experiment modeling nerve cell injury, MMF treatment reduced neuron loss from 80% down to 33%, while also improving measurable nerve function. The drug also decreased a stress response in glial cells that, when left unchecked, contributes to further tissue damage. This dual action, calming the immune attack while simultaneously protecting the cells under attack, is what makes fumarate-based drugs distinct from MS treatments that only suppress immunity.
Dosing and How to Take It
Vumerity uses a one-week ramp-up schedule to help your body adjust. You start at 231 mg twice a day for the first seven days, then increase to the maintenance dose of 462 mg (two 231 mg capsules) twice a day. The capsules are delayed-release, meaning they’re designed to dissolve further along in your digestive tract rather than in your stomach. Taking them with food can help reduce stomach discomfort during the early weeks.
Why It’s Easier on the Stomach Than Tecfidera
Since Vumerity delivers the same active metabolite as Tecfidera, the obvious question is why it exists at all. The answer is tolerability. The EVOLVE-MS-2 trial directly compared the two drugs in patients with relapsing-remitting MS and found that Vumerity reduced the number of days patients experienced moderate or worse GI symptoms by 46%. Only 0.8% of Vumerity patients stopped the drug because of GI side effects, compared with 4.8% on Tecfidera. Overall discontinuation due to any adverse event was also lower: 1.6% versus 5.6%.
The difference comes down to chemistry. When Vumerity is broken apart by esterases, its major byproduct (HES) is inert and doesn’t irritate the gut lining the way the methanol produced during Tecfidera’s breakdown can. More than 90% of Vumerity’s metabolism goes through this cleaner pathway.
Common Side Effects
The two most frequent side effects of fumarate drugs are flushing and GI symptoms like nausea, diarrhea, and abdominal pain. Flushing, which feels like a sudden warmth or redness in the skin, occurred in about 37% of patients taking fumarate therapy in early clinical trials (compared to 5% on placebo). These episodes are most common during the first three months and tend to resolve on their own. When flushing does occur, the median duration of an individual episode is about 17 days before it stops recurring. GI events follow a similar pattern, peaking early and declining as your body adjusts.
Monitoring While on Treatment
Before starting Vumerity, your doctor will order a complete blood count with differential and a comprehensive metabolic panel. The blood count matters because fumarate drugs can lower lymphocyte levels, a type of white blood cell critical for immune function. Periodic blood work continues throughout treatment to ensure lymphocyte counts stay within a safe range. A significant, sustained drop would prompt a conversation about whether to continue the medication, since very low lymphocyte counts can increase your risk of infections.